Aquestive Therapeutics, Inc.
AQST
$4.39
-$0.08-1.68%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 50.27M | 44.55M | 43.40M | 44.13M | 54.23M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.27M | 44.55M | 43.40M | 44.13M | 54.23M |
| Cost of Revenue | 18.37M | 18.56M | 17.24M | 17.17M | 17.14M |
| Gross Profit | 31.90M | 25.99M | 26.16M | 26.96M | 37.09M |
| SG&A Expenses | 71.75M | 79.85M | 63.04M | 59.91M | 58.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 106.16M | 115.60M | 99.19M | 96.73M | 95.41M |
| Operating Income | -55.89M | -71.05M | -55.79M | -52.60M | -41.18M |
| Income Before Tax | -68.91M | -83.78M | -68.99M | -65.06M | -54.25M |
| Income Tax Expenses | -- | -- | -14.00K | -14.00K | -14.00K |
| Earnings from Continuing Operations | -68.91 | -83.78 | -68.98 | -65.04 | -54.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.91M | -83.78M | -68.98M | -65.04M | -54.24M |
| EBIT | -55.89M | -71.05M | -55.79M | -52.60M | -41.18M |
| EBITDA | -55.34M | -70.48M | -55.20M | -51.99M | -40.51M |
| EPS Basic | -0.60 | -0.78 | -0.70 | -0.69 | -0.58 |
| Normalized Basic EPS | -0.38 | -0.49 | -0.43 | -0.42 | -0.37 |
| EPS Diluted | -0.60 | -0.78 | -0.70 | -0.69 | -0.58 |
| Normalized Diluted EPS | -0.38 | -0.49 | -0.43 | -0.42 | -0.37 |
| Average Basic Shares Outstanding | 454.49M | 427.38M | 396.61M | 377.11M | 368.69M |
| Average Diluted Shares Outstanding | 454.49M | 427.38M | 396.61M | 377.11M | 368.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |